Global Muscle Relaxant Drugs Market Trends, Forecast Report 2025-2037
Muscle Relaxant Drugs Market size is predicted to expand from USD 3.43 million to USD 8.06 million, reflecting a CAGR of over 6.9% during the forecast timeline, from 2025 to 2037. In the year 2025, the industry size of muscle relaxant drugs is estimated at USD 3.62 million.
The market growth can be ascribed to rising number of populations suffering from musculoskeletal conditions worldwide, along with patients with lower back pain. As per recent statistics provided by the Global Burden of Disease (GBD) in the year 2019, more than 1.71 billion people live with musculoskeletal conditions around the globe. A common problem noticed worldwide is deteriorating muscle health and an increase in muscle spasms. An upsurge in problems such as muscle cramps, sprains and strains, fibromyalgia, tendinitis, neuromuscular disorders, and many more diseases has been observed worldwide.
Muscle Relaxant Drugs Sector: Growth Drivers and Challenges
Growth Drivers
- Increasing Sedentary Lifestyle and Decreasing Activity Levels – is a crucial reason amongst all other reasons responsible for increasing muscle weakness and musculoskeletal diseases, and is expected to drive the demand for muscle relaxant drugs in the projected period. For instance, global estimates show 81% of adolescents and 1 in 4 adults do not indulge in enough physical activity. Levels of inactivity in economically developed countries are as high as 70%.
- Rising Number of Patients with Lower Back Pain - according to the World Health Organization, 570 million people are suffering from low back pain worldwide, contributing to 7.4% of years lived with disability (YLDs) across the globe.
- Upsurge in the Number of People Suffering from Osteoarthritis (OA) – it was found that there were 527.81 million prevalent cases of OA globally in 2019.
- Growing Geriatric Population - according to the World Health Organization in 2019, there are 1 billion people aged 60 years and older. The number is expected to increase to 1.4 billion by 2030 and 2.1 billion by 2050.
- Rising Number of Cases Related to Fibromyalgia – as per estimates, fibromyalgia affects approximately 4 million US adults, about 2% of the total adult population.
Challenges
- Restrictions on the Use of Muscle Relaxants – which are mostly restricted for pregnant women and alcohol-addicted people. Muscle relaxants when combined with alcohol, may result in confusion, drowsiness, and errors in judgment.
- Side effects Associated with Liver Dysfunctional Problems and Respiratory Organs
- Short-term Relief Provider
Muscle Relaxant Drugs Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
6.9% |
|
Base Year Market Size (2024) |
USD 3.43 million |
|
Forecast Year Market Size (2037) |
USD 8.06 million |
|
Regional Scope |
|
Muscle Relaxant Drugs Segmentation
Therapeutic Group (Neuromuscular Blockers, Spasmolytic)
The neuromuscular blockers segment is anticipated to garner the largest muscle relaxant market revenue share by the end of 2037, backed by growing number of patients with neuromuscular disorders worldwide, with increasing number of people working remotely. According to the data, between 2019 and 2021, approximately 13 million people were registered every year for neuromuscular diagnosis in the United Kingdom.
Our in-depth analysis of the global muscle relaxant drugs market includes the following segments:
|
By Therapeutic Group |
|
|
By Formulation |
|
|
By Route of Administration |
|
|
By End-User |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportMuscle Relaxant Drugs Industry - Regional Synopsis
North America Market Forecast
The North America muscle relaxant drugs market is expected to account for largest revenue share by the end of 2037, backed by upsurge in healthcare expenditure, low physical activity along with the high prevalence of musculoskeletal conditions affecting people of all ages in the region. According to the American Medical Association's (AMA) Policy Research Perspective (PRP) report, the National Health Expenditures (NHE) increased by 9.7 percent and became 19.7 percent of GDP in the year 2020.
Companies Dominating the Muscle Relaxant Drugs Landscape
- AbbVie Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Antisense Therapeutics Limited
- Sandoz International GmbH
- Abbott Laboratories
- Pfizer, Inc.
- Merck & Co., Inc.
- SteriMax Inc.
- Vertical Pharmaceuticals, LLC
- Instas Pharmaceuticals Ltd.
- F. Hoffmann-La Roche Ltd.
In the News
-
AbbVie Inc., announced the approval of upadacitinib (RINVOQ) for the treatment of active non-radiographic axial spondyloarthritis in patients with signs of inflammation who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).
-
Antisense Therapeutics Limited- announced a scientific exploration into a new muscle disease indication for ATL1102 – Limb Girdle Muscular Dystrophy R2.
Author Credits: Radhika Pawar
- Report ID: 486
- Published Date: Jan 17, 2025
- Report Format: PDF, PPT
